Researchers at the George Washington University School of Medicine and Health Sciences in partnership with Baylor College of Medicine report encouraging results from a phase 2 clinical trial evaluating a candidate vaccine to prevent hookworm infection—one of the world’s most common parasitic diseases. The findings, published in The Lancet Infectious Diseases, show that a formulation of the investigational vaccine significantly reduced the intensity of infection in healthy adult volunteers exposed to the parasite under carefully controlled conditions.
This article was originally published on MedicalXpress.com
